In continuation of my update on Telaprevir...............
Tuesday, July 12, 2011
Monday, July 11, 2011
Sunday, July 10, 2011
FDA Approves Xarelto (rivaroxaban) to Prevent Deep Vein Thrombosis
We know that, Rivaroxaban (structure below BAY 59-7939) is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceuticals. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible....
Now FDA Approves Xarelto (rivaroxaban) to Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery....
More....
Saturday, July 9, 2011
Sulforaphane-rich foods safe and effective for preventing cancer
In continuation of my update on the benefits of broccoli and sulforaphane............
Labels:
anticancer activity,
broccoli,
sulforaphane
Thursday, July 7, 2011
New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease
We know that Bardoxolone methyl (see the structure, also known as “RTA 402” and “CDDO-methyl ester) is an orally-available first-in-class synthetic triterpenoid belonging to the antioxidant inflammation modulator (AIM) class. It is the most potent known inducer of the Nrf2 pathway to enter clinical development and works to suppress both oxidative stress and inflammation.......
Labels:
Bardoxolone methyl,
diabetes type 2function,
kidney
Wednesday, July 6, 2011
Sunday, July 3, 2011
Saturday, July 2, 2011
New and effective diabetes drug seeking approval
We know that, Dapagliflozin is an experimental drug being studied by Bristol-Myers Squibb in partnership with AstraZeneca as a potential treatment for type 1 and 2 diabetes. Although dapagliflozin's method of action would operate on either type of diabetes or other conditions resulting in hyperglycemia, the current clinical trials specifically exclude participants with Type 1 diabetes.Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucosereabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.
New and effective diabetes drug seeking approval
New and effective diabetes drug seeking approval
Friday, July 1, 2011
Wednesday, June 29, 2011
Wednesday, June 22, 2011
Tuesday, June 21, 2011
Subscribe to:
Posts (Atom)